Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
softacort augndropar, lausn í stakskammtaíláti 3,35 mg/ml
laboratoires thea* - hydrocortisonum natríumfosfat - augndropar, lausn í stakskammtaíláti - 3,35 mg/ml
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
taflotan sine (taflotan) augndropar, lausn 15 míkróg/ml
santen oy* - tafluprostum inn - augndropar, lausn - 15 míkróg/ml
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
travoprost/timolol medical valley augndropar, lausn 40 míkróg/ml + 5 mg/ml
medical valley invest ab - travoprostinum inn; timololum maleat - augndropar, lausn - 40 míkróg/ml + 5 mg/ml
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
venofer stungulyf, lausn 20 mg/ml
vifor france - ferri oxidum saccharated (sykurflétta) - stungulyf, lausn - 20 mg/ml
Եվրոպական Միություն -
իսլանդերեն -
EMA (European Medicines Agency)
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - Æxlishemjandi lyf - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
Եվրոպական Միություն -
իսլանդերեն -
EMA (European Medicines Agency)
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - forvarnarfrumuæxli-eitilfrumuhvítblæði - Æxlishemjandi lyf - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
Եվրոպական Միություն -
իսլանդերեն -
EMA (European Medicines Agency)
teriparatide sun
sun pharmaceutical industries europe b.v. - teriparatíð - osteoporosis; osteoporosis, postmenopausal - kalsíumsterastasis - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.